Skip to main content Accessibility help

Secondary, profound, sensorineural hearing loss after recovery from haemolytic uraemic syndrome due to enterohaemorrhagic Escherichia coli, and subsequent cochlear implantation, in two Japanese children

  • S B Minami (a1), H Takegoshi (a2), Y Shinjo (a1) and K Kaga (a1) (a2)



To describe two cases of profound hearing loss secondary to enterohaemorrhagic Escherichia coli infection, and to report the efficacy of subsequent cochlear implantation.


The first case was a four-year-old girl admitted to hospital with Escherichia coli O157 infection and haemolytic uraemic syndrome. Mild hearing loss was confirmed five months after discharge, progressing to profound loss three months later. At the age of seven years, she underwent cochlear implantation, with remarkable improvement in speech perception and production. The second case was a three-year-old boy admitted with haemolytic uraemic syndrome caused by Escherichia coli O111 infection. One year after disease onset, profound hearing loss was confirmed. Cochlear implantation at the age of five years produced significant recovery of auditory function.


This study represents the first published report of secondary hearing loss after recovery from haemolytic uraemic syndrome caused by enterohaemorrhagic Escherichia coli. It indicates that cochlear implantation can restore hearing function in such patients.


Corresponding author

Address for correspondence: Dr Shujiro B Minami, 2-5-1 Higashigaoka Meguro-ku, Tokyo 152-8902, Japan Fax: +81 3 3412 9811 E-mail:


Hide All
1Caprioli, A, Morabito, S, Brugere, H, Oswald, E. Enterohaemorrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet Res 2005;36:289311
2Nataro, JP, Kaper, JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11:142201
3Pennington, H. Escherichia coli O157. Lancet 2010;376:1428–35
4Griffin, PM, Tauxe, RV. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev 1991;13:6098
5Scheiring, J, Andreoli, SP, Zimmerhackl, LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008;23:1749–60
6Tozzi, AE, Caprioli, A, Minelli, F, Gianviti, A, De Petris, L, Edefonti, A et al. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988–2000. Emerg Infect Dis 2003;9:106–8
7Gerber, A, Karch, H, Allerberger, F, Verweyen, HM, Zimmerhackl, LB. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. J Infect Dis 2002;186:493500
8Tarr, PI, Gordon, CA, Chandler, WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073–86
9Siegler, R,Oakes, R. Hemolytic uremic syndrome; pathogenesis, treatment, and outcome. Curr Opin Pediatr 2005;17:200–4
10Karpman, D, Sartz, L, Johnson, S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:575–85
11Sandvig, K. Shiga toxins. Toxicon 2001;39:1629–35
12Zheng, XL, Sadler, JE. Pathogenesis of thrombotic microangiopathies. Ann Rev Pathol 2008;3:249–77
13Lin, CD, Wei, IH, Tsai, MH, Kao, MC, Lai, CH, Hsu, CJ et al. Changes in guinea pig cochlea after transient cochlear ischemia. Neuroreport 2010;21:968–75
14Frank, C, Werber, D, Cramer, JP, Askar, M, Faber, M, An Der Heiden, M et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011;365:1771–80



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed